Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (12852)	8/28/2003 8:22:59 PM
From: axial	Read Replies (2) \| Respond to of 14101

"As jamieb7 on SH understood clearly the real question is when does the sales growth plateau. It'll have to slow down first before it stops and so far it hasn't done that either." ~~~~~~~~~~~~~~~~~~~~~~~~~~ And, as everyone's aware, these figures are for Canada only. With roughly 3 times as many reps detailing in Italy, can we expect corresponding success? It doesn't seem unreasonable. "In the meantime the right response is to be very skeptical of this." One can never go wrong being sceptical, around here. We have a cohort of bashers that have elevated scepticism to an art form, roughly equivalent to scatalogical graffiti. Not directed at you Wolf, but my question is "What's wrong with being optimistic? What the hell is wrong with saying we have a good product, with many uses, and this is just the beginning?" The curve may plateau at some point - or the rate of increase may slowly decrease for a long time before it finally levels off. That could take a year or two. The product is doing well. The launch was done as well as could be expected, given the constraints. It's a certainty that DMX won't be flying any prescribers to some lush tropical isle for a week, where believers can sip drinkies with little umbrellas in them, as they digest the contents of Pennsaid "seminars". People are prescribing Pennsaid because the rationale for its use makes sense, and because the product works. ~~~~~~~~~~~~~~~~~~~~~~~~~~ And since at least one of us is being optimistic, lets not forget the impact of these accelerating sales on other aspects of DMX's future. While Pennsaid sales are a drop in the bucket in terms of anticipated R&D costs, each $100,000 retained is $100,000 that DMX doesn't have to borrow for operations - and that has consequences in any anticipated future financing. Finally, as others have pointed out, when it comes time to finally ink a deal with a US distributor, its performance in Canada will be noted, and factored into the result. Those who don't think that has any importance, or relevance, should try extrapolating the Canadian numbers in the context of a US launch. Not too shabby - even without DTC advertising. No offense to anyone here, but scepticism, doubt and fear pervade this stock. It is not unreasonable to suggest what we have believed for years - that Pennsaid is a good product, which will have a good market. What we are finally seeing is merely the expected result of that long-held belief - which is as it should be. Jim